Citigroup
NKTR icon

Citigroup’s Nektar Therapeutics NKTR Stock Holding History

Citigroup’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,353
Closed -$109K – 6512
2022
Q1 		$109K Buy
+1,353
New +$200K ﹤0.01% 4370
2021
Q1 		– Sell
-2,733
Closed -$697K – 7021
2020
Q4 		$697K Buy
2,733
+1,380
+102% +$357K ﹤0.01% 3912
2020
Q3 		$337K Sell
1,353
-1,780
-57% -$560K ﹤0.01% 4197
2020
Q2 		$1.09M Sell
3,133
-334
-10% -$104K ﹤0.01% 3472
2020
Q1 		$928K Sell
3,467
-273
-7% -$84.4K ﹤0.01% 3252
2019
Q4 		$1.21M Sell
3,740
-167
-4% -$48.4K ﹤0.01% 3562
2019
Q3 		$1.07M Buy
3,907
+1,967
+101% +$721K ﹤0.01% 3575
2019
Q2 		$1.03M Buy
1,940
+833
+75% +$418K ﹤0.01% 3582
2019
Q1 		$558K Sell
1,107
-2,520
-69% -$1.49M ﹤0.01% 4071
2018
Q4 		$1.79M Buy
3,627
+1,727
+91% +$1.04M ﹤0.01% 2775
2018
Q3 		$1.74M Sell
1,900
-3,853
-67% -$3.29M ﹤0.01% 2892
2018
Q2 		$4.21M Buy
5,753
+5,320
+1,229% +$6.13M ﹤0.01% 2004
2018
Q1 		$691K Sell
433
-767
-64% -$988K ﹤0.01% 3642
2017
Q4 		$1.07M Buy
1,200
+573
+91% +$339K ﹤0.01% 3269
2017
Q3 		$226K Buy
627
+227
+57% +$71K ﹤0.01% 4886
2017
Q2 		$117K Sell
400
-13
-3% -$3.76K ﹤0.01% 5233
2017
Q1 		$146K Sell
413
-374
-48% -$84.1K ﹤0.01% 4912
2016
Q4 		$145K Sell
787
-3,246
-80% -$660K ﹤0.01% 5543
2016
Q3 		$1.04M Buy
4,033
+3,073
+320% +$791K ﹤0.01% 3173
2016
Q2 		$205K Buy
960
+513
+115% +$115K ﹤0.01% 4480
2016
Q1 		$92K Buy
447
+280
+168% +$53.8K ﹤0.01% 5722
2015
Q4 		$42K Buy
+167
New +$34.3K ﹤0.01% 6060
2015
Q3 		– Sell
-1,333
Closed -$250K – 7590
2015
Q2 		$250K Buy
+1,333
New +$229K ﹤0.01% 4263
2013
Q4 		– Sell
-1,840
Closed -$288K – 7091
2013
Q3 		$288K Buy
+1,840
New +$340K ﹤0.01% 3861

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's NKTR Position: Q2 2026 in Review

Citigroup increased its Nektar Therapeutics (NKTR) stake by 310% in Q2 2026, buying an estimated $5.69M and bringing the position to 102,760 shares worth $7.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1852.

Citigroup first reported a position in NKTR in Q2 2013 and has held it in 53 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Citigroup held 102,760 shares of Nektar Therapeutics worth $7.17M as of Q2 2026.
  • Citigroup bought 77,712 Nektar Therapeutics shares in Q2 2026, an estimated $5.69M.
  • Nektar Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1852 holding.
  • Citigroup first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.